

# Neelanjana Ray

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11588473/publications.pdf>

Version: 2024-02-01

14  
papers

779  
citations

623188

14  
h-index

1058022

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

995  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>In Vitro</i> Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3498-3507.	1.4	118
2	Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2012, 206, 1002-1011.	1.9	92
3	Transcriptional Response of a Common Permissive Cell Type to Infection by Two Diverse Alphaherpesviruses. <i>Journal of Virology</i> , 2004, 78, 3489-3501.	1.5	80
4	Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors. <i>Journal of Virology</i> , 2007, 81, 3240-3250.	1.5	68
5	Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4172-4180.	1.4	67
6	Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 573-581.	1.3	56
7	HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 13-24.	0.5	54
8	HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide. <i>Journal of Virology</i> , 2009, 83, 2989-2995.	1.5	52
9	Study of Andes virus entry and neutralization using a pseudovirion system. <i>Journal of Virological Methods</i> , 2010, 163, 416-423.	1.0	40
10	Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. <i>Virology</i> , 2009, 387, 296-302.	1.1	39
11	Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 7-15.	0.9	38
12	Cyclooxygenase-1 and -2 Are Required for Production of Infectious Pseudorabies Virus. <i>Journal of Virology</i> , 2004, 78, 12964-12974.	1.5	37
13	Maraviroc in the treatment of HIV infection. <i>Drug Design, Development and Therapy</i> , 2009, 2, 151.	2.0	21
14	Baseline Resistance of Primary Human Immunodeficiency Virus Type 1 Strains to the CXCR4 Inhibitor AMD3100. <i>Journal of Virology</i> , 2008, 82, 11695-11704.	1.5	17